Comparison of Two Methods for Estimating Absolute Risk of Prostate Cancer Based on Single Nucleotide Polymorphisms and Family History

Disease risk–associated single nucleotide polymorphisms (SNP) identified from genome-wide association studies have the potential to be used for disease risk prediction. An important feature of these risk-associated SNPs is their weak individual effect but stronger cumulative effect on disease risk. Several approaches are commonly used to model the combined effect in risk prediction, but their performance is unclear. We compared two methods to model the combined effect of 14 prostate cancer risk–associated SNPs and family history for the estimation of absolute risk for prostate cancer in a population-based case-control study in Sweden (2,899 cases and 1,722 controls). Method 1 weighs each risk allele equally using a simple method of counting the number of risk alleles, whereas method 2 weighs each risk SNP differently based on its odds ratio. We found considerable differences between the two methods. Absolute risk estimates from method 1 were generally higher than those of method 2, especially among men at higher risk. The difference in the overall discriminative performance, measured by area under the curve of the receiver operating characteristic, was small between method 1 (0.614) and method 2 (0.618), P = 0.20. However, the performance of these two methods in identifying high-risk individuals (2- or 3-fold higher than average risk), measured by positive predictive values, was higher for method 2 than for method 1. These results suggest that method 2 is superior to method 1 in estimating absolute risk if the purpose of risk prediction is to identify high-risk individuals. Cancer Epidemiol Biomarkers Prev; 19(4); 1083–8. ©2010 AACR.

[1]  Kari Stefansson,et al.  Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility , 2009, Nature Genetics.

[2]  Peter Kraft,et al.  Identification of a new prostate cancer susceptibility locus on chromosome 8q24 , 2009, Nature Genetics.

[3]  Ali Amin Al Olama,et al.  Multiple loci on 8q24 associated with prostate cancer susceptibility , 2009, Nature Genetics.

[4]  H. Grönberg,et al.  Estimation of absolute risk for prostate cancer using genetic markers and family history , 2009, The Prostate.

[5]  Ali Amin Al Olama,et al.  Identification of seven new prostate cancer susceptibility loci through a genome-wide association study , 2009, Nature Genetics.

[6]  J. Stanford,et al.  Analysis of Recently Identified Prostate Cancer Susceptibility Loci in a Population-based Study: Associations with Family History and Clinical Features , 2009, Clinical Cancer Research.

[7]  J. Carpten,et al.  Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer , 2009, The Prostate.

[8]  R. Wilkins Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[9]  M. Thun,et al.  Variation in KLK genes, prostate-specific antigen and risk of prostate cancer , 2008, Nature Genetics.

[10]  J. Carpten,et al.  Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12 , 2008, Nature Genetics.

[11]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[12]  Kevin M. Bradley,et al.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer , 2008, Nature Genetics.

[13]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[14]  Pär Stattin,et al.  Cumulative association of five genetic variants with prostate cancer. , 2008, The New England journal of medicine.

[15]  J. Carpten,et al.  Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. , 2007, Journal of the National Cancer Institute.

[16]  Yu Cheng,et al.  Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. , 2007, Journal of the National Cancer Institute.

[17]  D. Gudbjartsson,et al.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes , 2007, Nature Genetics.

[18]  D. Gudbjartsson,et al.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 , 2007, Nature Genetics.

[19]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[20]  A. Whittemore,et al.  Multiple regions within 8q24 independently affect risk for prostate cancer , 2007, Nature Genetics.

[21]  Jinbo Chen,et al.  Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.

[22]  A. Gylfason,et al.  A common variant associated with prostate cancer in European and African populations , 2006, Nature Genetics.

[23]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[24]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[25]  W. Dupont Converting relative risks to absolute risks: a graphical approach. , 1986, Statistics in medicine.